ReviewInternational journal of chronic obstructive pulmonary disease2010
Influencing the decline of lung function in COPD: use of pharmacotherapy.
Review in International journal of chronic obstructive pulmonary disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD.Therapeutic advances in respiratory diseasePooled it
- Long-term pulmonary outcomes in BPD throughout the life-course.Journal of perinatology : official journal of the California Perinatal Association · 2026Review
- Rapid FEVJournal of Korean medical science · 2023Article
- Bronchopulmonary dysplasia as a determinant of respiratory outcomes in adult life.Pediatric pulmonology · 2021Article
- Rate of Decline of FEVAmerican journal of respiratory and critical care medicine · 2021Article
- Pubertal onset with adulthood lung function mediated by height growth in adolescence.ERJ open research · 2020Article
- Review
- Decline in FEVInternational journal of chronic obstructive pulmonary disease · 2019Article
- Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada.International journal of chronic obstructive pulmonary disease · 2019Article
- Dynamics of airway response in lung microsections: a tool for studying airway-extra cellular matrix interactions.Journal of biomedical science · 2016Review
- 2,2'-Azobis (2-Amidinopropane) Dihydrochloride Is a Useful Tool to Impair Lung Function in Rats.Frontiers in physiology · 2016Article
- Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.British journal of clinical pharmacology · 2014Review
- Review
- The effect of adipose derived stromal cells on oxidative stress level, lung emphysema and white blood cells of guinea pigs model of chronic obstructive pulmonary disease.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2014Article
- Adipose-derived stromal cell therapy affects lung inflammation and tracheal responsiveness in guinea pig model of COPD.PloS one · 2014Article
- Sleep-disordered breathing and COPD: the overlap syndrome.Respiratory care · 2010Review
- Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. One of the hallmarks of COPD is an accelerated decline in lung function, as measured by spirometry. Inflammation, oxidative stress and other pathways are hypothesized to be important in this deterioration. Because progressive airflow obstruction is associated with considerable morbidity and mortality, a major goal of COPD treatment has been to slow or prevent the accelerated decline in lung function. Until recently, the only known effective intervention was smoking cessation. However, newly reported large clinical trials have shown that commonly used medications may help slow the rate of lung function decline. The effect of these medications is modest (and thus required such large, expensive trials) and to be of clinical benefit, therapy would likely need to start early in the course of disease and be prolonged. Such a treatment strategy aimed at preservation of lung function would need to be balanced against the side effects and costs of prolonged therapy. A variety of newer classes of medications may help target other pathophysiologically important pathways, and could be used in the future to prevent lung function decline in COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.